AMR Action Fund head aims to boost innovation, funds for new antibiotics

  04 February 2022

CIDRAP News spoke with AMR Action Fund CEO Henry Skinner, PhD, about the current state of antibiotic development, the need to fix the broken market for new antibiotics, and how to build a sustainable pipeline.

Many large pharmaceutical companies have abandoned antibiotic research and development (R&D) because of the poor return on investment. Smaller companies have gone bankrupt after getting a new antibiotic approved, for the very same reason. Multiple analyses have found that the pipeline to replace some of the antibiotics we’ve relied on for decades has some very good candidates for deadly, multidrug-resistant pathogens, but not enough. And too few of them are truly innovative.

Further reading: CIDRAP
Author(s): Chris Dall
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed